Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021PsoriasisPsoriatic Arthritis
Rheumatologic disease activity an important influencer of COVID-19 death riskFebruary 5, 2021COVID-19 UpdatesPsoriatic ArthritisInfectious Diseases
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)February 5, 2021Psoriatic ArthritisPediatrics
In head-to-head trial, two biologics differ markedly for control of psoriasisFebruary 4, 2021PsoriasisPsoriatic Arthritis
Guselkumab maintains psoriasis efficacy long after discontinuationJanuary 26, 2021PsoriasisPsoriatic Arthritis
Deucravacitinib offers biologic-like psoriasis efficacy in oral formJanuary 8, 2021PsoriasisPsoriatic Arthritis
COVID-19 vaccines: Safe for immunocompromised patients?December 17, 2020COVID-19 UpdatesInfectious DiseasesPsoriasisPsoriatic Arthritis
Synovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic ArthritisPsoriasis
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic ArthritisPsoriasis
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possibleNovember 25, 2020PsoriasisPsoriatic Arthritis
Tildrakizumab for psoriasis shows durable efficacy over 5 yearsNovember 19, 2020PsoriasisPsoriatic Arthritis
Methotrexate users need tuberculosis tests in high-TB areasNovember 8, 2020Psoriatic ArthritisPediatricsAutoimmune DiseasesPsoriasisInfectious Diseases
